Medical Device User Fee Rates for Fiscal Year 2006, 46872-46874 [05-15863]
Download as PDF
46872
Federal Register / Vol. 70, No. 154 / Thursday, August 11, 2005 / Notices
into the annual financial and
programmatic reports. All indicators
need to be drawn from the Emergency
Plan.
3. Financial status report, no more
than 90 days after the end of the budget
period. The financial report must show
obligations, disbursements and funds
remaining by program activity.
Indicators must be developed for each
program milestone and incorporated
into the periodic financial and
programmatic reports. All indicators
need to be drawn from The Emergency
Plan Indicator Guide.
4. Final performance reports, no more
than 90 days after the end of the project
period.
Recipients must mail these reports to
the Grants Management or Contract
Specialist listed in the ‘‘Agency
Contacts’’ section of this announcement.
VII. Agency Contacts
We encourage inquiries concerning
this announcement. For general
questions, contact: Technical
Information Management Section, CDC
Procurement and Grants Office, U.S.
Department of Health and Human
Services, 2920 Brandywine Road,
Atlanta, GA 30341. Telephone: 770–
488–2700.
For program technical assistance,
contact: Kathy Grooms, Project Officer,
Global AIDS Program, HHS/CDC
National Center for HIV, STD, and TB
Prevention, 1600 Clifton Road, Mailstop
E–04, Atlanta, GA 30333. Telephone:
404–639–8394.
For financial, grants management, or
budget assistance, contact: Vivian
Walker, Grants Management Specialist,
CDC Procurement and Grants Office,
U.S. Department of Health and Human
Services, 2920 Brandywine Road,
Atlanta, GA 30341. Telephone: 770–
488–2724. E-mail: vwalker@cdc.gov.
VIII. Other Information
Applicants can find this and other
HHS/CDC funding opportunity
announcements on the HHS/CDC web
site, Internet address: https://
www.cdc.gov (Click on ‘‘Funding,’’ then
‘‘Grants and Cooperative Agreements’’),
and on the web site of the HHS Office
of Global Health Affairs, Internet
address: https://www.globalhealth.gov.
Dated: August 5, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention,
U.S. Department of Health and Human
Services.
[FR Doc. 05–15893 Filed 8–10–05; 8:45 am]
BILLING CODE 4163–18–P
VerDate jul<14>2003
16:14 Aug 10, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Program Announcement AA134]
Strengthening HIV/AIDS, TB and STI
Prevention, Control and Treatment
Activities Within the Police Force of
Ethiopia; Notice of Intent To Fund
Single Eligibility Award
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005 funds for
a cooperative agreement program to
strengthen the activities in the
prevention, control, and treatment of
HIV/AIDS, Sexually Transmitted
Infections (STI) and Tuberculosis (TB)
within the Police Force of Ethiopia. The
project particularly aims to: (1) Improve
HIV/AIDS, STI and TB prevention
following the Abstinence, Be Faithful,
and Correct and Consistent Condom Use
(ABC) strategies, care and treatment
services within the Police Force of
Ethiopia; (2) strengthen human resource
capacity of the police force for HIV/
AIDS/STI/TB services; and (3)
implement and support targeted
monitoring and evaluation. The Catalog
of Federal Domestic Assistance number
for this program is 93.067.
B. Eligible Applicant
Assistance will be provided only to
the FPC of the Federal Democratic
Republic of Ethiopia for this project.
The FPC of Ethiopia is the most
appropriate and qualified agency to
conduct the activities because:
1. FPC’s HIV Prevention and Control
Office is the only office uniquely
positioned in terms of legal authority,
ability, and credibility to coordinate and
support prevention, care, and treatment
activities among members of the police
force and their dependents.
2. The FPC administers all the police
force health facilities which constitute
the only facilities where members of the
police force and their dependents
receive care.
3. FPC is the umbrella entity that can
access the police force and their
dependents at the national and regional
levels.
4. FPC is mandated by the Federal
Government of Ethiopia to work on
HIV/AIDS in behalf of the police force
and their dependants with international
organizations and civil societies in the
prevention and control of HIV/AIDS.
5. The Police Hospital is the only
referral hospital for the police and their
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
dependants in the country playing a
leading role in providing an integrated
and comprehensive HIV/AIDS treatment
and care and serving also as a major
training center for all cadres of health
care professionals deployed at the
police force health facilities in the
country that also integrate training,
service and research.
C. Funding
Approximately $140,000 is available
in FY 2005 to fund this award on
September 15, 2005, and will be made
for a 12-month budget period within a
project period of up to five years.
Funding estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146. Telephone: 770–488–2700.
For technical questions about this
program, contact: Tadesse Wuhib, MD,
MPH, Country Director, CDC-Ethiopia,
P.O. Box 1014, Entoto Road, Addis
Ababa. Telephone: (Office) 251–1–66–
95–33; (Cell) 251–9–228543. E-mail
address: wuhibt@etcdc.com.
Dated: August 4, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–15894 Filed 8–10–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Medical Device User Fee Rates for
Fiscal Year 2006
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
fee rates and payment procedures for
medical device user fees for fiscal year
(FY) 2006. The Federal Food, Drug, and
Cosmetic Act (the act), as amended by
the Medical Device User Fee and
Modernization Act of 2002 (MDUFMA)
and the Medical Device User Fee
Stabilization Act of 2005 (MDUFSA),
authorizes FDA to collect user fees for
certain medical device applications. The
FY 2006 fee rates are provided in this
notice. For all applications submitted on
or after October 1, 2005, and through
September 30, 2006, fees must be paid
E:\FR\FM\11AUN1.SGM
11AUN1
Federal Register / Vol. 70, No. 154 / Thursday, August 11, 2005 / Notices
at the FY 2006 rates at the time the
applications are submitted to FDA. The
fee you must pay is the fee that is in
effect on the date your application is
received by FDA or on the date your
check is received, whichever is later.
This notice provides details on how fees
for FY 2006 were determined and
payment procedures for medical device
applications subject to user fees.
FOR FURTHER INFORMATION CONTACT:
For further information on MDUFMA:
Visit the FDA Web site https://
www.fda.gov/cdrh/mdufma.
For questions relating to this notice:
Frank Claunts, Office of
Management (HF–20), Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–
827–4427.
SUPPLEMENTARY INFORMATION:
I. Background
Section 738 of the act (21 USC 379j)
establishes fees for certain medical
device applications and supplements.
Under statutorily defined conditions,
FDA may waive or reduce fees (21
U.S.C. 379j(d) and (e)).
Under MDUFMA, the fee rate for each
type of application is set at a specified
percentage of the standard fee for a
premarket application (a premarket
application is a premarket approval
application (PMA), a product
development protocol, or a biologic
licensing application). MDUFSA
specifies that the standard fee for a
premarket application submitted during
FY 2006 is $259,600. From this starting
point, this notice establishes fee rates
for FY 2006. These fees are effective on
October 1, 2005, and will remain in
effect through September 30, 2006.
II. Fee Calculations for FY 2006
Under the act, all fees are set as a
percentage of the full fee for a premarket
application (see 21 U.S.C. 379j(a)(1)(A)),
and the act sets the standard fee for a
premarket application at $259,600 for
FY 2006 (see 21 U.S.C. 379j(c)(1); this is
46873
referred to as the ‘‘base fee.’’ A 180-day
supplement is set at 21.5 percent of the
base fee; the fee for a real-time
supplement is set at 7.2 percent of the
base fee (see 21 U.S.C. 379j(a)(1)(A)).
For all applications other than
premarket notification submissions
(510(k)s), the small business rate is 38
percent of the standard (full fee) rate
(see 21 U.S.C. 379j(d)(2)(C)). For 510(k)
premarket notification submissions, the
fees are to be set so that fees from all
510(k)s would produce revenue as if all
were assessed a fee of 1.42 percent of
the base fee, but these fee rates are to be
adjusted so that the fee paid by a
qualifying small business is 80 percent
of the full rate for a 510(k) premarket
notification submission (see 21 U.S.C.
379j(e)(2)(C)). Based on FDA’s estimates,
about 19 percent of 510(k) premarket
notifications will qualify for the small
business fee, and about 81 percent will
pay the standard (full) fee. The FY 2006
fee rates for all application categories
are set out in table 1 of this document.
TABLE 1.—FEE TYPES, PERCENT OF PMA FEE, AND FY 2006 FEE RATES
Full Fee Amount as a
Percent of Premarket Application Fee
Application Fee Type
FY 2006 Full Fee
PMA (submitted under section 515(c)(1) or 515(f) of the act
or section 351 of the Public Health Service Act)
FY 2006 Small Business
Fee
$259,600
$98,648
Premarket Reporting (submitted under section 515(c)(2) of
the act)
100%
$259,600
$98,648
Panel Track Supplement
100%
$259,600
$98,648
Efficacy Supplement (to an approved premarket application
under section 351 of the PHS Act)
100%
$259,600
$98,648
180-Day Supplement
21.5%
$55,814
$21,209
Real Time Supplement
7.2%
$18,691
$7,103
1.42% in aggregate
$3,833
$3,066
510(k)
III. Small Business Qualification for
Purposes of MDUFMA Fees
Firms with annual gross sales or
receipts of $30 million or less, including
the gross sales and receipts of all
affiliates, partners, and parent firms,
may qualify for a fee waiver for their
first PMA. Firms with annual gross sales
or receipts of $100 million or less,
including the gross sales and receipts of
all affiliates, partners, and parent firms,
may qualify for lower rates for all
applications that are subject to a fee.
Even if a firm qualified under the act
as a small business for MDUFMA fees
in FY 2005, it must obtain a new small
business certification and decision
number for FY 2006 and for each
subsequent FY. This can be initiated
VerDate jul<14>2003
16:14 Aug 10, 2005
Jkt 205001
any time after the publication of this
notice. A firm that does not have an FY
2006 small business qualification
decision number from FDA will not be
permitted to submit the reduced small
business fees for applications submitted
during FY 2006. FDA urges firms to
apply for this qualification at least 60
days before they intend to submit their
application and fee.
To qualify, you are required to submit
the following:
(1) A completed FY 2006 Small
Business Qualification Certification
(Form FDA 3602). This form is provided
in FDA’s guidance document, FY 2006
MDUFMA Small Business Qualification
Worksheet and Certification, available
on FDA’s Web site at https://
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
www.fda.gov/cdrh/mdufma. This form
is not available separate from the
guidance document.
(2) Certified copies of your Federal
Income Tax Return for the most recent
taxable year (2004 or later), and certified
copies of the income tax returns of your
affiliates, partners, and parent firms.
You can find information for
determining if an applicant qualifies for
a small business first-time PMA waiver
and lower rates for subsequent
applications on the FDA Web site at
https://www.fda.gov/cdrh/mdufma,
under the heading ‘‘Guidance
Documents,’’ click on the link
‘‘Qualifying as a Small Business.’’ This
Web site provides detailed instructions
and the address for mailing
E:\FR\FM\11AUN1.SGM
11AUN1
46874
Federal Register / Vol. 70, No. 154 / Thursday, August 11, 2005 / Notices
documentation to support qualification
as a small business under MDUFMA.
IV. Procedures for Paying Application
Fees
Any application or supplement
subject to fees under MDUFMA that is
received on or after October 1, 2005,
through September 30, 2006, is subject
to the FY 2006 fee rate. The later of the
date that the application is received in
the reviewing center’s document room
or the date that the check is received by
US Bank determines whether the fee
rates for FY 2005 or FY 2006 apply.
FDA must receive the correct fee at the
time that an application is submitted, or
the application will not be accepted for
filing or review.
FDA requests that you follow the
steps below before submitting a medical
device application subject to a fee.
Please pay close attention to these
procedures to ensure that FDA links the
fee with the correct application. (Note:
In no case should the check for the fee
be submitted to FDA with the
application.)
A. Step One—Secure a Payment
Identification Number and Medical
Device User Fee Cover Sheet From FDA
Before Submitting Either the
Application or the Payment. Note: FY
2006 Fee Rates Will be Available on the
Cover Sheet Web Site Beginning on
September 6, 2005
Log onto the MDUFMA Web site at
https://www.fda.gov/oc/mdufma and
under the forms heading, click on the
link ‘‘User Fee Cover Sheet.’’ Complete
the Medical Device User Fee Cover
Sheet. Be sure you choose the correct
application submission date range. (Two
choices will be offered from September
6 until October 1, 2005. One choice is
for applications that will be received on
or before September 30, 2005, which
will be subject to FY 2005 fee rates. A
second choice is for applications that
will be received on or after October 1,
2005, which will be subject to FY 2006
fee rates.) After completing data entry,
print a copy of the Medical Device User
Fee Cover Sheet and note the unique
Payment Identification Number located
in the upper right-hand corner of the
printed cover sheet.
B. Step Two—Electronically Transmit a
Copy of the Printed Cover Sheet with the
Payment Identification Number to
FDA’s Office of Financial Management
Once you are satisfied that the data on
the cover sheet is accurate,
electronically transmit that data to FDA
according to instructions on the screen.
Since electronic transmission is
possible, applicants are required to set
VerDate jul<14>2003
16:14 Aug 10, 2005
Jkt 205001
up a user account and use passwords to
assure data security in the creation and
electronic submission of cover sheets.
C. Step Three—Mail Payment and a
Copy of the Completed Medical Device
User Fee Cover Sheet to the St. Louis
Address Specified Below
• Make the payment in U.S. currency
by check, bank draft, or U.S. Postal
money order payable to the Food and
Drug Administration. (The tax
identification number of the Food and
Drug Administration is 53–0196965,
should your accounting department
need this information.)
• Please write your application’s
unique Payment Identification Number,
from the upper right-hand corner of
your completed Medical Device User
Fee Cover Sheet, on your check, bank
draft, or U.S. Postal money order.
• Mail the payment and a copy of the
completed Medical Device User Fee
Cover Sheet to: Food and Drug
Administration, P.O. Box 956733, St.
Louis, MO, 63195–6733.
If you prefer to send a check by a
courier (such as FEDEX, DHL, UPS,
etc.), the courier may deliver the check
to: US Bank, Attn: Government Lockbox
956733, 1005 Convention Plaza, St.
Louis, MO 63101.
(Note: This address is for courier
delivery only. Contact the US Bank at
314–418–4821 if you have any questions
concerning courier delivery.)
It is helpful if the fee arrives at the
bank at least 1 day before the
application arrives at FDA. FDA records
the official application receipt date as
the later of the following:
• The date the application was
received by FDA.
• The date US Bank receives the
payment. US Bank is required to notify
FDA within 1 working day, using the
Payment Identification Number
described previously.
D. Step Four—Submit your Application
to FDA with a Copy of the Completed
Medical Device User Fee Cover Sheet
Please submit your application and a
copy of the completed Medical Device
User Fee Cover Sheet to one of the
following addresses:
• Medical device applications should
be submitted to: Food and Drug
Administration, Center for Devices and
Radiological Health, Document Mail
Center (HFZ–401), 9200 Corporate
Blvd., Rockville, MD 20850.
• Biologic applications should be sent
to: Food and Drug Administration,
Center for Biologics Evaluation and
Research, Document Control Center
(HFM–99), suite 200N, 1401 Rockville
Pike, Rockville, MD 20852–1448.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Dated: August 5, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–15863 Filed 8–10–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Program Exclusions: July 2005
AGENCY:
Office of Inspector General,
HHS.
ACTION:
Notice of program exclusions.
During the month of July 2005, the
HHS Office of Inspector General
imposed exclusions in the cases set
forth below. When an exclusions is
imposed, no program payment is made
to anyone for any items or services
(other than an emergency item or
service not provided in a hospital
emergency room) furnished, ordered or
prescribed by an excluded party under
the Medicare, Medicaid, and all Federal
Health Care programs. In addition, no
program payment is made to any
business or facility, e.g., a hospital, that
submits bills for payment for items or
services provided by an excluded party.
Program beneficiaries remain free to
decide for themselves whether they will
continue to use the services of an
excluded party even though no program
payments will be made for items and
services provided by that excluded
party. The exclusions have national
effect and also apply to all Executive
Branch procurement and nonprocurement programs and activities.
Subject, city, state
Effective
date
PROGRAM-RELATED CONVICTIONS
AFSHARIAN, PAYAM ..............
SANTA MONICA, CA
AQUATIC & PHYSICAL THERAPY ASSOCIATES ...............
KALAMAZOO, MI
AWAHMUKALAH, MARGARET
AVONDALE, PA
BERGMAN, BARBARA ............
RHINELANDER, WI
BILLS, BETTY ..........................
OPA LOCKA, FL
BROWN, KELENKA .................
E CHICAGO, IN
CABALLERO, HERMINIO ........
MIAMI, FL
CAP PHARMACY, INC ............
DENVER, CO
CERDA, LOURDES ..................
FONTANA, CA
COCHRAN, JUDITH .................
GUTHRIE, OK
DANIELS, LANISHA .................
E:\FR\FM\11AUN1.SGM
11AUN1
8/18/2005
8/18/2005
8/18/2005
8/18/2005
8/18/2005
8/18/2005
8/18/2005
12/13/2004
8/18/2005
8/18/2005
8/18/2005
Agencies
[Federal Register Volume 70, Number 154 (Thursday, August 11, 2005)]
[Notices]
[Pages 46872-46874]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15863]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Medical Device User Fee Rates for Fiscal Year 2006
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the fee
rates and payment procedures for medical device user fees for fiscal
year (FY) 2006. The Federal Food, Drug, and Cosmetic Act (the act), as
amended by the Medical Device User Fee and Modernization Act of 2002
(MDUFMA) and the Medical Device User Fee Stabilization Act of 2005
(MDUFSA), authorizes FDA to collect user fees for certain medical
device applications. The FY 2006 fee rates are provided in this notice.
For all applications submitted on or after October 1, 2005, and through
September 30, 2006, fees must be paid
[[Page 46873]]
at the FY 2006 rates at the time the applications are submitted to FDA.
The fee you must pay is the fee that is in effect on the date your
application is received by FDA or on the date your check is received,
whichever is later. This notice provides details on how fees for FY
2006 were determined and payment procedures for medical device
applications subject to user fees.
FOR FURTHER INFORMATION CONTACT:
For further information on MDUFMA: Visit the FDA Web site https://
www.fda.gov/cdrh/mdufma.
For questions relating to this notice: Frank Claunts, Office of
Management (HF-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-4427.
SUPPLEMENTARY INFORMATION:
I. Background
Section 738 of the act (21 USC 379j) establishes fees for certain
medical device applications and supplements. Under statutorily defined
conditions, FDA may waive or reduce fees (21 U.S.C. 379j(d) and (e)).
Under MDUFMA, the fee rate for each type of application is set at a
specified percentage of the standard fee for a premarket application (a
premarket application is a premarket approval application (PMA), a
product development protocol, or a biologic licensing application).
MDUFSA specifies that the standard fee for a premarket application
submitted during FY 2006 is $259,600. From this starting point, this
notice establishes fee rates for FY 2006. These fees are effective on
October 1, 2005, and will remain in effect through September 30, 2006.
II. Fee Calculations for FY 2006
Under the act, all fees are set as a percentage of the full fee for
a premarket application (see 21 U.S.C. 379j(a)(1)(A)), and the act sets
the standard fee for a premarket application at $259,600 for FY 2006
(see 21 U.S.C. 379j(c)(1); this is referred to as the ``base fee.'' A
180-day supplement is set at 21.5 percent of the base fee; the fee for
a real-time supplement is set at 7.2 percent of the base fee (see 21
U.S.C. 379j(a)(1)(A)).
For all applications other than premarket notification submissions
(510(k)s), the small business rate is 38 percent of the standard (full
fee) rate (see 21 U.S.C. 379j(d)(2)(C)). For 510(k) premarket
notification submissions, the fees are to be set so that fees from all
510(k)s would produce revenue as if all were assessed a fee of 1.42
percent of the base fee, but these fee rates are to be adjusted so that
the fee paid by a qualifying small business is 80 percent of the full
rate for a 510(k) premarket notification submission (see 21 U.S.C.
379j(e)(2)(C)). Based on FDA's estimates, about 19 percent of 510(k)
premarket notifications will qualify for the small business fee, and
about 81 percent will pay the standard (full) fee. The FY 2006 fee
rates for all application categories are set out in table 1 of this
document.
Table 1.--Fee Types, Percent of PMA Fee, and FY 2006 Fee Rates
----------------------------------------------------------------------------------------------------------------
Full Fee Amount as a
Application Fee Type Percent of Premarket FY 2006 Full Fee FY 2006 Small Business
Application Fee Fee
----------------------------------------------------------------------------------------------------------------
PMA (submitted under section ........................... $259,600 $98,648
515(c)(1) or 515(f) of the act
or section 351 of the Public
Health Service Act)
----------------------------------------------------------------------------------------------------------------
Premarket Reporting (submitted 100% $259,600 $98,648
under section 515(c)(2) of the
act)
----------------------------------------------------------------------------------------------------------------
Panel Track Supplement 100% $259,600 $98,648
----------------------------------------------------------------------------------------------------------------
Efficacy Supplement (to an 100% $259,600 $98,648
approved premarket application
under section 351 of the PHS
Act)
----------------------------------------------------------------------------------------------------------------
180-Day Supplement 21.5% $55,814 $21,209
----------------------------------------------------------------------------------------------------------------
Real Time Supplement 7.2% $18,691 $7,103
----------------------------------------------------------------------------------------------------------------
510(k) 1.42% in aggregate $3,833 $3,066
----------------------------------------------------------------------------------------------------------------
III. Small Business Qualification for Purposes of MDUFMA Fees
Firms with annual gross sales or receipts of $30 million or less,
including the gross sales and receipts of all affiliates, partners, and
parent firms, may qualify for a fee waiver for their first PMA. Firms
with annual gross sales or receipts of $100 million or less, including
the gross sales and receipts of all affiliates, partners, and parent
firms, may qualify for lower rates for all applications that are
subject to a fee.
Even if a firm qualified under the act as a small business for
MDUFMA fees in FY 2005, it must obtain a new small business
certification and decision number for FY 2006 and for each subsequent
FY. This can be initiated any time after the publication of this
notice. A firm that does not have an FY 2006 small business
qualification decision number from FDA will not be permitted to submit
the reduced small business fees for applications submitted during FY
2006. FDA urges firms to apply for this qualification at least 60 days
before they intend to submit their application and fee.
To qualify, you are required to submit the following:
(1) A completed FY 2006 Small Business Qualification Certification
(Form FDA 3602). This form is provided in FDA's guidance document, FY
2006 MDUFMA Small Business Qualification Worksheet and Certification,
available on FDA's Web site at https://www.fda.gov/cdrh/mdufma. This
form is not available separate from the guidance document.
(2) Certified copies of your Federal Income Tax Return for the most
recent taxable year (2004 or later), and certified copies of the income
tax returns of your affiliates, partners, and parent firms.
You can find information for determining if an applicant qualifies
for a small business first-time PMA waiver and lower rates for
subsequent applications on the FDA Web site at https://www.fda.gov/cdrh/
mdufma, under the heading ``Guidance Documents,'' click on the link
``Qualifying as a Small Business.'' This Web site provides detailed
instructions and the address for mailing
[[Page 46874]]
documentation to support qualification as a small business under
MDUFMA.
IV. Procedures for Paying Application Fees
Any application or supplement subject to fees under MDUFMA that is
received on or after October 1, 2005, through September 30, 2006, is
subject to the FY 2006 fee rate. The later of the date that the
application is received in the reviewing center's document room or the
date that the check is received by US Bank determines whether the fee
rates for FY 2005 or FY 2006 apply. FDA must receive the correct fee at
the time that an application is submitted, or the application will not
be accepted for filing or review.
FDA requests that you follow the steps below before submitting a
medical device application subject to a fee. Please pay close attention
to these procedures to ensure that FDA links the fee with the correct
application. (Note: In no case should the check for the fee be
submitted to FDA with the application.)
A. Step One--Secure a Payment Identification Number and Medical Device
User Fee Cover Sheet From FDA Before Submitting Either the Application
or the Payment. Note: FY 2006 Fee Rates Will be Available on the Cover
Sheet Web Site Beginning on September 6, 2005
Log onto the MDUFMA Web site at https://www.fda.gov/oc/mdufma and
under the forms heading, click on the link ``User Fee Cover Sheet.''
Complete the Medical Device User Fee Cover Sheet. Be sure you choose
the correct application submission date range. (Two choices will be
offered from September 6 until October 1, 2005. One choice is for
applications that will be received on or before September 30, 2005,
which will be subject to FY 2005 fee rates. A second choice is for
applications that will be received on or after October 1, 2005, which
will be subject to FY 2006 fee rates.) After completing data entry,
print a copy of the Medical Device User Fee Cover Sheet and note the
unique Payment Identification Number located in the upper right-hand
corner of the printed cover sheet.
B. Step Two--Electronically Transmit a Copy of the Printed Cover Sheet
with the Payment Identification Number to FDA's Office of Financial
Management
Once you are satisfied that the data on the cover sheet is
accurate, electronically transmit that data to FDA according to
instructions on the screen. Since electronic transmission is possible,
applicants are required to set up a user account and use passwords to
assure data security in the creation and electronic submission of cover
sheets.
C. Step Three--Mail Payment and a Copy of the Completed Medical Device
User Fee Cover Sheet to the St. Louis Address Specified Below
Make the payment in U.S. currency by check, bank draft, or
U.S. Postal money order payable to the Food and Drug Administration.
(The tax identification number of the Food and Drug Administration is
53-0196965, should your accounting department need this information.)
Please write your application's unique Payment
Identification Number, from the upper right-hand corner of your
completed Medical Device User Fee Cover Sheet, on your check, bank
draft, or U.S. Postal money order.
Mail the payment and a copy of the completed Medical
Device User Fee Cover Sheet to: Food and Drug Administration, P.O. Box
956733, St. Louis, MO, 63195-6733.
If you prefer to send a check by a courier (such as FEDEX, DHL,
UPS, etc.), the courier may deliver the check to: US Bank, Attn:
Government Lockbox 956733, 1005 Convention Plaza, St. Louis, MO 63101.
(Note: This address is for courier delivery only. Contact the US
Bank at 314-418-4821 if you have any questions concerning courier
delivery.)
It is helpful if the fee arrives at the bank at least 1 day before
the application arrives at FDA. FDA records the official application
receipt date as the later of the following:
The date the application was received by FDA.
The date US Bank receives the payment. US Bank is required
to notify FDA within 1 working day, using the Payment Identification
Number described previously.
D. Step Four--Submit your Application to FDA with a Copy of the
Completed Medical Device User Fee Cover Sheet
Please submit your application and a copy of the completed Medical
Device User Fee Cover Sheet to one of the following addresses:
Medical device applications should be submitted to: Food
and Drug Administration, Center for Devices and Radiological Health,
Document Mail Center (HFZ-401), 9200 Corporate Blvd., Rockville, MD
20850.
Biologic applications should be sent to: Food and Drug
Administration, Center for Biologics Evaluation and Research, Document
Control Center (HFM-99), suite 200N, 1401 Rockville Pike, Rockville, MD
20852-1448.
Dated: August 5, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-15863 Filed 8-10-05; 8:45 am]
BILLING CODE 4160-01-S